Modelling the Effectiveness of Ibrutinib Versus Rituximab-Based Chemotherapy Regimens in Relapsed/Refractory Mantle Cell Lymphoma

Nov 1, 2016, 00:00 AM
10.1016/j.jval.2016.09.2212
https://www.valueinhealthjournal.com/article/S1098-3015(16)33578-1/fulltext
Section Title : Disease-Specific Studies
Section Order : 2099
First Page : A733
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)33578-1&doi=10.1016/j.jval.2016.09.2212
HEOR Topics :
Tags :
Regions :